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Abstract: The immunosuppressive drugs used to prevent the rejection of transplanted organs 
have a narrow therapeutic index. Under treatment results in episodes of rejection leading to 
either damage or loss of the organ. Over immunosuppression increases the risk of infection and 
malignancy as well as drug specific complications including diabetes mellitus and  nephrotoxicity. 
There is wide variation in the drug dose required to achieve target blood concentrations and there 
is often dissociation between pharmacokinetics and pharmacodynamics. Currently, immunosup-
pressive drug treatment is individualized based on a clinical assessment of the risk of rejection 
or toxicity. Therapeutic drug monitoring is routinely employed for several immunosuppressive 
drugs. Pharmacogenetics has the potential to complement therapeutic drug monitoring but clinical 
benefit has yet to be demonstrated. Novel biomarker-based approaches to risk stratification and 
pharmacodynamic monitoring are under development and are ready for clinical trials.
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Introduction
Immunosuppresion is of fundamental importance to the long-term survival of trans-
planted organs. Over the last 50 years there have been great advances in our  knowledge 
of the immune system and the potential therapeutic targets for pharmacological 
intervention leading to improved patient and graft survival. Despite this, the rate 
of allograft loss per year is around 3%−5% with major improvements in short term 
outcomes failing to translate into the same magnitude of benefit in the long term.1 
As the number of acute rejection episodes has decreased, the complications associ-
ated with long-term immunosuppression have become increasingly evident. This has 
driven research into reducing the toxic effects of immunosuppression. Perhaps the 
greatest challenge to the clinician is the ever growing demand to tailor therapy to 
suit individual patient characteristics, and balance the advantages and disadvantages 
of these treatments.
Overview of immunosuppressive drug treatment
The immune system can be targeted at several levels. It is always important to remem-
ber that any reduction in immune responsiveness to the allograft is accompanied by 
reduced immunity to infection and malignant disease, in particular DNA viruses 
such as cytomegalovirus, Epstein–Barr virus, and BK polyomavirus, which causes 
 nephropathy and renal allograft loss.
Prospective study data have indicated that acute rejection is an important pre-
dictor of long-term graft function, therefore many interventions have focused on 
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 minimizing acute rejection episodes. Industry-sponsored 
studies  conducted as part of the licensing process for new 
drugs have tended to focus on the short term outcomes of 
early acute rejection rate and 1 year graft survival. As a 
consequence the evidence base for optimal immunosup-
pressive treatment in the early period after transplantation 
is strong with much weaker evidence to indicate optimal 
long-term therapy.
Induction immunosuppressive 
therapy
Episodes of acute rejection occur most common in the early 
period after transplantation and are rare beyond 3 months 
after transplantation with most immunosuppressive regimens. 
This has been achieved largely through the use of induction 
therapy in the peritransplantation period (Table 1). The term 
“induction therapy” refers to potent agents given during 
the early period after transplantation that are not continued 
long term. In the United States between 1998 and 2007, a total 
of 78% of renal transplant recipients received antibody induc-
tion therapy.2 Induction agents can be grouped into drugs 
causing cell depletion (lytic induction) and drugs blocking 
cell surface receptors without depletion (nonlytic induction). 
In general, lytic induction agents are more potent with lower 
rates of acute rejection but higher incidence of infectious and 
malignant complications. The only nonlytic induction agent 
in widespread use is basiliximab, a monoclonal antibody 
specific for the alpha chain of the interleukin (IL)-2  receptor 
expressed on activated T-lymphocytes. Frequently used 
lytic induction agents include rabbit antithymocyte globulin 
(ATG; Thymoglobulin®; SangStat Medical Corporation, 
Fremont, CA), a lymphocyte depleting polyclonal antibody. 
The recent introduction of alemtuzumab, a humanized 
 monoclonal antibody that is specific for CD52 and depletes 
T- and B-lymphocytes, natural killer cells, and monocytes 
has seen increasing use. One large, prospective, randomized 
controlled trial showed that despite superior prevention of 
biopsy confirmed acute rejection at 6, 12, and 36 months 
compared to basiliximab, alemtuzumab was associated with 
persistent leukopenia and a higher rate of serious infections.2 
Late episodes of acute rejection in the period 3−12 months 
after transplantation are more common in alemtuzumab-
treated patients than with other regimens.2 Normally one of 
these induction agents is also combined with either a short 
course of corticosteroid therapy or longer term  corticosteroid 
use as well as introduction of the maintenance regimen 
described below. Given the advantages and disadvantages of 
all the agents available and the multiple different regimens, 
it is still not clear which is the best formula. ATG is the most 
commonly used agent and is very potent, whereas basiliximab 
is less potent but offers fewer complications. The choice of 
regimen depends on an assessment of the risks of rejection 
and complications of over immunosuppression.
Maintenance immunosuppressive 
therapy
Maintenance immunosuppression may be best achieved with 
a combination approach although some clinicians prefer cal-
cineurin inhibitor (CNI) monotherapy. Combination therapy 
aims to minimize the side effects of any single drug whilst 
maintaining adequate overall immunosuppression. The prin-
ciple is to target multiple levels of lymphocyte activation and 
inflammation. This is achieved by combining corticosteroids 
with a CNI (cyclosporin or tacrolimus) and an antiprolifera-
tive agent such as azathioprine or mycophenolate (Table 2). 
Several factors such as degree of human leukocyte antigen 
incompatibility, presence of human leukocyte antigen anti-
body, recipient ethnic group, previous transplants, and history 
of previous acute rejection influence the choice and dosage of 
specific maintenance agents, based on risk of acute  rejection 
or toxicity. The potential for use of more sophisticated mark-
ers for risk stratification is discussed below.
Maintenance therapies widely used 
in solid organ transplant recipients
Azathioprine
Azathioprine was developed in the early 1960s and functions 
as an antimetabolite to decrease lymphocyte DNA and RNA 
synthesis. A more recently identified mechanism of action is 
the inhibition of intracellular signaling following activation 
Table 1 Induction immunosuppression drugs
Drug Mechanism of action Side effects
ATG/ALG Complement mediated lysis  
Opsonization and clearance  
blockade of cell surface  
receptors
Agranulocytosis 
Thrombocytopenia 
Cytokine release  
syndrome
Basiliximab  
(anti-CD25  
antibody)
Blockade of IL-2 receptor
Alemtuzumab T and B lymphocyte depletion Cytokine release  
syndrome
OKT3 Complement-mediated lysis  
opsonization and clearance  
blockade of CD3 receptor
Cytokine release  
syndrome
Abbreviations: ATG, antithymocyte globulin; ALG, antilymphocyte globulin; 
IL-2, interleukin-2; OKT3, monoclonal anti-CD3 antibody.
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of the CD28 pathway.3 Side effects of azathioprine include 
leukopenia, thrombocytopenia, gastrointestinal disturbance, 
hepatitis, cholestasis, and alopecia. Consequently, blood 
counts need to be monitored regularly as myelosuppres-
sion can be potentially fatal. Azathioprine is free from any 
important metabolic or cardiovascular toxicities.
Corticosteroids
Corticosteroids have long been the main therapeutic agent 
during induction and maintenance of immunosuppression. 
Their mechanism of action involves inhibiting a broad 
range of cytokines, including IL-1 and IL-6 production by 
 macrophages as well as all stages of T-lymphocyte  activation. 
Corticosteroids are also very effective when used at high 
doses to treat episodes of acute rejection. The long-term 
complications associated with corticosteroid use are well 
documented and include hypertension, diabetes mellitus, 
cataracts, osteoporosis, hyperlipidemia, and  infections.4 
Corticosteroid-free immunosuppression is gaining  popularity 
given that a large proportion of transplant loss is related 
to cardiovascular mortality and/or fatal infectious com-
plications and that the long-term use of corticosteroids 
contributes to an adverse cardiovascular risk factor profile. 
With progressive improvement in the potency of the other 
immunosuppressive drugs, corticosteroid-avoidance or 
minimization can often be achieved. A large reduction in 
the number of patients being discharged on corticosteroids 
has reflected the trend of corticosteroid-free treatment or 
at least  minimal corticosteroid use.5 Benefits obtained include 
decreased blood cholesterol and triglyceride  concentrations, 
decreased blood pressure medication requirement,6–8 
and lower rates of new onset diabetes after transplanta-
tion (NODAT),9,10 cardiovascular events, and metabolic 
syndrome.11,12 Despite the advantages of corticosteroid-free 
immunosuppression, acute rejection remains lower in patients 
receiving corticosteroid-containing regimens.5
Calcineurin inhibitors (CNI)
Cyclosporin
Introduced in the 1980s, cyclosporin binds to the intracel-
lular molecule cyclophilin and the complex inhibits the 
phosphatase calcineurin. This in turn prevents the dephos-
phorylation of nuclear factor of activated T-lymphocytes 
with consequent inhibition of IL-2 synthesis. IL-2 is a key 
cytokine in driving the proliferation of T-lymphocytes. On 
introduction of cyclosporin, 1 year survival rates for renal 
allografts improved from approximately 60% to between 
80% and 90%.13 Cyclosporin is associated with nephrotoxic-
ity due to vasoconstriction causing ischemia and direct toxic 
effects on renal tubular epithelial cells, which has driven 
attempts to find alternative drugs.14 While it was hoped that 
a more recently introduced CNI, tacrolimus, would be less 
 nephrotoxic, this is not clear from the available published 
data.15 In one report, nearly all 99 recipients of kidney– 
pancreas transplants who received cyclosporin-based immuno-
suppression had nephrotoxicity 10 years after transplantation, 
Table 2 Maintenance immunosuppression drugs
Drug Mechanism of action Side effects
Corticosteroids Blocks transcription of cytokine genes, IL-1, IL-2, IL-3, IL-5, IL-6, tumor  
necrosis factor-α, and interferons
Hypertension 
Glucose intolerance 
Dyslipidemia 
Osteoporosis
Cyclosporin Inhibits IL-2 production, stimulates TGF-β production Nephrotoxicity 
Hypertension 
Dyslipidemia 
Glucose intolerance
Tacrolimus Inhibits IL-2 production Nephrotoxicity 
Hypertension 
Dyslipidemia 
Glucose intolerance
Azathioprine Inhibits purine synthesis and blocks DNA and RNA synthesis 
Inhibits CD28 signaling
Myelosuppression
Mycohphenolate mofetil Blocks de novo pathway of purine synthesis (selective for lymphocytes)  
and blocks glycosylation
Diarrhea and gastrointestinal upset 
Myelosuppression
Sirolimus/everolimus Blocks IL-2-induced cell cycle progression Hyperlipidemia  
Thrombocytopenia 
Impaired wound healing 
Oral ulcers
Belatacept Blocks costimulation by CD28 PTLD in EBv naïve patients
Abbreviations: EBv, Epstein-Barr virus; IL, interleukin; PTLD, posttransplant lymphoproliferative disorder; TGF, transforming growth factor.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
65
Individualized immunosuppression in transplant patients
Pharmacogenomics and Personalized Medicine 2012:5
with the median onset of the first lesion at 6 months.16  However, 
histological changes ascribed to CNI toxicity have been ques-
tioned recently with similar changes found in patients not 
treated with CNIs.17 Its side effect profile has led to several 
studies aiming to minimize CNI use. One such study was the 
CAESAR trial,18 which compared graft function 12 months 
postoperatively among patients randomly assigned to one 
of three groups; daclizumab (a CD25 antibody that has now 
been withdrawn from the market for commercial reasons), 
mycophenolate mofetil (MMF), corticosteroid, and low-dose 
cyclosporin (target trough concentrations of 50–100 ng/mL), 
weaned from month 4 and withdrawn by month 6;  daclizumab, 
MMF, corticosteroid, and low-dose cyclosporin; or MMF, 
corticosteroid, and standard-dose cyclosporin. The main 
aim was to determine if withdrawing cyclosporin would 
provide appropriate immunosuppression but this was not 
the case, with higher rates of acute rejection episodes in the 
cyclosporin withdrawal group. However, the low-dose group 
provided similar if not better results at 12 months compared 
to the standard group, which heralded the potential for CNI-
minimizing therapy.
Tacrolimus
The other currently licensed CNI is tacrolimus, a macrolide 
structurally related to the antibiotic erythromycin. It is 
more potent than cyclosporin, with some data19 suggesting 
improved graft survival; but this comes at the expense of 
higher rates of NODAT and neurological symptoms including 
tremor and paresthesia. As mentioned above, tacrolimus is 
nephrotoxic,19 but it is associated with a lower incidence of 
hyperlipidemia and hypertension than cyclosporin.20 This is 
important because cardiovascular disease is the most common 
cause of premature death in transplant recipients.21
The most widely used immunosuppressive regimen 
for renal transplantation is based on the results of the 
ELITE–Symphony trial,22 in which 1645 renal transplant 
recipients were randomized to receive either standard-dose 
cyclosporin, MMF, and corticosteroids, or daclizumab 
induction, MMF, and corticosteroids, in combination with 
low-dose cyclosporin, low-dose tacrolimus, or low-dose 
sirolimus. Treatment for 12 months with a regimen con-
taining daclizumab, MMF, corticosteroids, and low-dose 
tacrolimus provided adequate immunosuppression compared 
to the other three treatment groups as evidenced by better 
renal function and renal allograft survival, and lower rates 
of acute rejection. In addition, the low-dose tacrolimus 
regimen provided better allograft survival than regimens 
with standard-dose cyclosporin or low-dose sirolimus. 
This did come at the expense of a higher incidence of 
NODAT than with the other regimens and a higher incidence 
of diarrhea, which may reflect excessive MMF dosing. This 
study has paved the way for lower doses of CNIs while still 
providing effective immunosuppression with a concomitant 
reduction in the risks associated with these medications.22
Other authors have looked at eliminating the adverse 
effects of CNIs by discontinuing their use in immuno-
logically low-risk patients, which has been associated with 
favorable long-term results.23,24 Bakker et al showed that 
conversion to a CNI-free immunosuppressive regimen 
3 months after renal transplantation improved allograft 
function, reduced the need for cardiovascular risk factor 
controlling medication, and reduced the incidence of chronic 
allograft nephropathy (now referred to as interstitial fibrosis 
with tubular atrophy).23
Mammalian target of rapamycin (mTOR) inhibitors
The mammalian target of rapamycin (mTOR) inhibitors 
block the response of T-lymphocytes to IL-2 and have 
additional antiproliferative effects. There are two drugs 
currently licensed in this class; sirolimus, a macrolide, and 
everolimus, which was derived by adding a hydroxyethyl 
group to  sirolimus. Sirolimus has a long-elimination half-life 
of 60 hours allowing once-daily dosing,25 in comparison to 
the shorter half-life of everolimus of 18–35 hours requiring 
twice-daily dosing.26 When initially introduced, it was hoped 
that the mTOR inhibitors would provide an alternative to the 
CNIs for use in de novo transplants that was not  nephrotoxic 
and did not cause hypertension. However, they are not 
quite as potent as the CNIs resulting in higher rates of acute 
 rejection, while the antiproliferative effects include impaired 
would healing, increased incidence of lymphoceles,27,28 and 
delayed recovery from acute tubular necrosis. The inhibition 
of the scarring process may be of benefit in reducing inter-
stitial fibrosis and tubular atrophy after the early transplant 
phase and a number of regimens now involve initial use of 
a CNI with switch to an mTOR inhibitor after the initial 
3-month period. The mTOR inhibitors can be used along 
with CNIs and this is the basis for the license for everolimus. 
A potential problem with this approach is the potentiation of 
CNI nephrotoxicity through inhibition of the drug transporter 
P-glycoprotein (P-gp) by sirolimus leading to increased 
intracellular drug concentration.29,30 Hypertriglyceridemia, 
hypercholesterolemia, microcytic anemia, and thrombocy-
topenia are also problems.
The mTOR inhibitors have anticancer properties.31 
Interestingly everolimus has been extensively studied in 
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the field of oncology as a potential treatment for renal cell 
carcinomas, neuroendocrine tumors of the intestine, mantle 
cell lymphoma, and sarcomas.
Barrier to absorption of the CNIs and mTOR inhibitors
The oral bioavailability of the CNIs and mTOR inhibitors is 
only in the order of 20%–30%. This is in part due to the active 
barrier to absorption posed through first pass metabolism in 
the intestine and liver by the enzymes cytochrome P450 3A4 
and 3A5 (CYP3A4, CYP3A5) and by the drug transporter 
P-gp (the product of the ABCB1 gene). A significant pro-
portion of the variation in oral bioavailability between 
 individuals and drug interactions are based on the effective-
ness of this barrier.32
Mycophenolate
The active drug mycophenolic acid is available as a mor-
pholinoethyl ester, MMF or as enteric-coated mycophenolate 
sodium. Mycophenolic acid inhibits the enzyme inosine 
monophosphate dehydrogenase (IMPDH) and impairs 
B- and T-lymphocyte proliferation, sparing other rapidly 
dividing cells. MMF is a more potent adjunct therapy used 
along with CNI than azathioprine.33 While acute rejection 
in the early period after transplantation is reduced, impact 
on longer term outcomes is less certain although there are 
some positive data.34
Belatacept
Belatacept is the most recently introduced immunosuppres-
sive drug. It is a fusion protein between a genetically modi-
fied CD152 (CTLA4) domain and a human immunoglobulin 
G domain. It blocks costimulation of T-lymphocytes via the 
CD28 pathway and requires intravenous administration, 
more frequently during the early period after transplanta-
tion and then monthly. When compared to cyclosporin, 
acute rejection rates were higher but there was less chronic 
damage on protocol biopsies. An increased incidence of 
posttransplant lymphoproliferative disorder in Epstein–Barr 
virus naïve patients is an important concern. The phar-
macokinetics of belatacept are predictable with limited 
variation between individuals, unlike the small molecule 
immunosuppressive drugs.35
Specific inhibition of antibody production
Acute and chronic antibody-mediated rejection are amongst 
the most difficult complications of transplantation to treat. 
Removal of donor-specific antibodies to allow transplantation 
in immunologically sensitized patients is another challenging 
area that is a focus of current research. The most widely used 
anti-B-lymphocyte agent is rituximab, a chimeric antibody to 
the CD20 molecule that is expressed on B-lymphocytes but 
not mature plasma cells or pro-B-lymphocytes. It has been 
used as an induction agent, along with intravenous immu-
noglobulin and antibody removal by immunoabsorption or 
plasma exchange, to reduce the rate of antibody resynthesis 
in antibody incompatible transplantation. There are some data 
to suggest efficacy in acute antibody mediated rejection and 
trials of efficacy in chronic antibody mediated rejection are 
underway.36 The proteasome inhibitor bortezomib depletes 
mature plasma cells offering direct targeting of the source 
of antibody production. There is evidence of bortezomib 
efficacy in acute antibody mediated rejection.37 One of the 
primary mechanisms of antibody mediated damage of vas-
cular endothelium is through the activation of complement. 
Eculizumab is an antibody specific for the C5 component 
of complement and inhibits the formation of the membrane 
attack complex preventing complement-mediated damage to 
cells. It has been used for both the prevention and treatment 
of acute antibody mediated rejection.38
Interindividual variability 
of transplant rejection and 
potential for individualized 
immunosuppression
Identification of patients at high  
risk of rejection or toxicity
In recent years the number of acute rejection episodes has 
decreased, therefore the main challenges are to reduce 
long-term toxicity and transplant damage due to chronic 
rejection, with an increasingly recognized role for chronic 
antibody mediated rejection. Multiple factors predispose 
chronic allograft damage, including the condition of the 
donor organ, ischemia reperfusion injury, acute or chronic 
immunological rejection, drug toxicity, hypertension, and 
infection.39 Identification of risk for acute rejection in both 
the short and long term would allow individualization of 
immunosuppressive treatment. An area of substantial recent 
activity has been the identification of patients with complete 
or partial immunological tolerance to transplantation to 
allow safe minimization of immunosuppression. The initial 
phase of this research was based on studies of noncompli-
ant patients who continued to have well-functioning grafts 
after complete immunosuppression withdrawal (operational 
tolerance).40,41 International consortia have identified a cross 
platform biomarker signature for operational tolerance 
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including expansion of peripheral blood B-lymphocytes, 
absence of donor specific antibodies, donor specific hypo-
responsiveness of CD4+ T-lymphocytes, and a high ratio of 
FoxP3 to α-1,2-mannosidase gene expression in peripheral 
blood.40,41 Attempts are now underway to qualify clinically 
useful biomarkers based on these data to allow targeted 
immunosuppression minimization or withdrawal.
Monitoring of response to 
immunosuppressive therapy
Assays of response to immunosuppression are close to clini-
cal application, or so called pharmacodynamic monitoring. 
These assays are based on measurement of the degree of 
inhibition of target enzymes or signaling pathways. Patients 
with significant residual expression of nuclear factor of acti-
vated T-lymphocyte regulated genes on treatment with CNI 
have a higher incidence of acute rejection than those with 
potent suppression, but are less susceptible to infection. This 
information could allow either use of an alternative agent 
or higher CNI blood concentrations.42 Similarly, assays of 
IMPDH activity have been proposed as a strategy for iden-
tification of response to MMF but there is wide variation 
in response between individuals, which will make clinical 
application challenging.43 Measurement of IMPDH activity in 
CD4+ T-lymphocytes represents a potential refinement of this 
approach.44 A variety of markers of inhibition of lymphocyte 
activation have been validated for testing in clinical trials.45 
There is a commercially available assay (Immuknow™; 
Cylex, Columbia, MD) that measures inhibition of the pro-
liferation of CD4+ T-lymphocytes in response to a mitogen. 
While rejection rates were higher and infection rates were 
lower, the wide variation within the groups again limits the 
clinical utility of this assay,46 a common flaw for all of the 
pharmacodynamic assays. Prospective data on the impact of 
pharmacodynamic monitoring on outcomes are awaited.
Potential for pharmacogenetics  
in clinical decision making
Therapeutic drug monitoring (TDM) is routinely used to 
achieve therapeutic blood concentrations of cyclosporin, 
tacrolimus, sirolimus, and everolimus. TDM has been used 
for MMF by some centers, although this is controversial.47 
Genetic factors influence pharmacokinetics and pharmaco-
genetic testing has potential as an adjunct to TDM. Genetic 
polymorphisms in drug targets, drug metabolizing enzymes, 
and drug transporters have been identified as potential targets 
for developing a pharmacogenetic strategy to individualize 
initial drug choice and dose.32 This is most likely to be useful 
where early achievement of target blood concentrations is 
important, for prevention of acute rejection, avoidance of sig-
nificant toxicity, or when there may be some delay using the 
reactive strategy of TDM. This is the case for cyclosporin,48 
tacrolimus,49 and MMF.50 Another area of potential utility is 
for drugs with a long-elimination half-life such as sirolimus, 
where the prolonged time to reach steady state after dose 
adjustments, in response to blood concentrations outside 
the target range, may result in significant delay in achieving 
target blood concentrations. Genotyping for mutations in 
the thiopurine-S-methyltransferase gene that metabolizes 
azathioprine has been widely adopted in some therapeutic 
areas but not transplantation.51 This may be due to frequent 
blood count monitoring in transplant recipients following the 
introduction of azathioprine allowing the avoidance of severe 
myelotoxicity. Potentially useful pharmacogenetic strategies 
to guide the prescription of immunosuppressive drugs are 
summarized in Table 3.
Table 3 Summary of potential pharmacogenetic strategies to guide immunosuppressive drug prescribing
Drug Genotypes Evidence Ref
Tacrolimus CYP3A5*1/*3 
 
CYP3A4*22 
POR*28
Tested in a randomized controlled trial with earlier achievement of target blood  
concentrations but no influence on clinical outcome. 
May provide additional predictive value to algorithms in combination with CYP3A5*1/*3.
58 
59 
60 
61
Sirolimus CYP3A5*1/*3 Impact on dose-normalized blood concentrations but not yet tested in a clinical trial. 67–69
Cyclosporin CYP3A5*1/*3 
CYP3A4*22
Combination of genotypes may predict drug exposure but not yet replicated. 66
Azathioprine TPMT Predicts individuals likely to develop severe myelotoxicity. Limited adoption 
in transplantation with no intervention study data.
51
Mycophenolate UGT1A9 
IMPDH1
Predicts individuals likely to be under-exposed to MPA with increased risk of rejection. 
Predicts individuals at increased risk of rejection. 
Genetic component to variability in MPA exposure is much smaller than other factors,  
limiting the potential of pharmacogenetics.
71 
72
Abbreviations: IMPDH, inosine monophosphate dehydrogenase; MPA, mycophenolic acid.
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Tacrolimus
The drug for which the potential application of pharma-
cogenetics has been most extensively tested is tacrolimus. 
Tacrolimus pharmacokinetics are influenced by a variety of 
factors including hepatic dysfunction, previous hepatitis C 
virus infection, time after transplantation, patient age, donor 
liver characteristics, recipient ethnic group, hematocrit 
and serum albumin concentrations, diurnal rhythm, food 
administration, corticosteroid dosage, diarrhea, and CYP 
isoenzyme and P-gp expression.52,53 A very crude form of 
pharmacogenetics that is applied in some centers is the 
administration of increased doses of tacrolimus to indi-
viduals who are genetically sub-Saharan African (Black).54 
Investigation of possible genetic factors underlying the high 
tacrolimus dose requirement in Black patients led to the 
identification of CYP3A5 expresser status as a key deter-
minant of the oral bioavailability of tacrolimus.55,56 People 
are either functional expressers or nonexpressers of the 
metabolic enzyme CYP3A5, a key component of the first 
pass barrier to drug absorption. Expression is determined 
by single nucleotide polymorphisms (SNPs) in the CYP3A5 
gene. Individuals with at least one wild-type CYP3A5*1 
allele are functional expressers and homozygotes for the 
mutant CYP3A5*3 allele are functional nonexpressers. 
CYP3A5 expressers take longer to achieve target blood 
tacrolimus concentrations after transplantation, require 
higher doses of tacrolimus, and experience episodes of 
acute rejection earlier than nonexpressers.57 An important 
caveat is that in immunosuppressive regimens based on 
potent induction therapy and other adjunctive agents, early 
attainment of target blood concentrations of tacrolimus 
may not be critical, resulting in absence of observed influ-
ence on the incidence of acute rejection in some studies.58 
A multicenter study in France randomized renal transplant 
recipients at relatively low risk of rejection to receive either 
a standard initial tacrolimus dose of 0.2 mg/kg or to a dose 
based on genotype: 0.3 mg/kg for CYP3A5 expressers or 
0.15 mg/kg for nonexpressers. The majority of patients were 
given high doses of ATG as induction therapy with high 
doses of MMF. Significantly more patients in the genetically 
predicted group achieved the target blood concentration 
within 3 days of starting treatment with tacrolimus than in 
the standard dose group (43.2% versus 29.1%, P = 0.03).59 
While this study achieved a modest improvement in the 
number of patients with blood concentrations within the 
target range, over half of the patients were still outside 
the range and there was no difference between the groups 
in incidence of acute rejection or toxicity. A key factor in 
the absence of positive pharmacodynamic endpoints was 
the delay in introduction of tacrolimus until 7 days after 
transplantation.
Addition of other genotypes into a more complex 
polygenic algorithm may allow refinement of the genetic 
 prediction. Other candidate genotypes that have been shown 
to have a significant influence on tacrolimus  pharmacokinetics 
are ABCB1 (encoding P-gp),55 CYP3A4*2260 and P450 
oxidoreductase*28.61 It may be useful to combine genetic 
and demographic factors62 but this algorithm remains to be 
tested on another cohort of patients. There has been recent 
interest in the pregnane X receptor that regulates the expres-
sion of cytochrome P450 and P-gp and its genetic variants 
as potential predictors of interindividual differences in drug 
concentrations.63 The extent of pregnane X receptor effects 
on immunosuppression in transplant patients has not been 
investigated.
Cyclosporin
Cyclosporin pharmacokinetics are, among other factors, 
influenced by body weight and concomitant prednisolone 
exposure, and genetic markers are yet to be identified that 
explain the interindividual variability.64 While CYP3A5 
genotype alone is not predictive of cyclosporin dose 
requirements,65 addition of the CYP3A4*22 genotype to the 
algorithm provides a better prediction but with a large degree 
of overlap between the genotype groups.66
Sirolimus and everolimus
The influence of CYP3A5 expression on the pharmacoki-
netics of sirolimus is less well studied. However, when pre-
scribed without a CNI, the oral bioavailability of sirolimus is 
lower in CYP3A5 expressers67 and consequently takes longer 
to achieve target blood concentrations than nonexpressers.68 
Furthermore, expressers require significantly more sirolimus 
to achieve adequate blood trough concentrations.69 There 
was no significant influence of CYP3A5 genotype on the 
pharmacokinetics of everolimus.70
MMF
MMF dose-prediction may be influenced by the expres-
sion of SNPs, which affect the metabolism, transport, and 
target enzyme for mycophenolic acid. The UGT1A9 and 
IMPDH1 genes contain SNPs which are predictive of acute 
rejection.71,72 However, there are no data on the use of these 
genotypes in guiding MMF dosing.
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Drug transporters
Drug transporters may be useful in developing a pharmaco-
genetic strategy for immunosuppression. The transporters 
influence toxicity, metabolism, and elimination of drugs 
within cells and are subject to genetic variation. One such 
transporter is P-gp, which is encoded by the ABCB1 gene. 
In theory, higher concentrations of P-gp on T-lymphocytes 
will lead to reduced intracellular concentrations of immu-
nosuppressant drugs. It has been demonstrated that ABCB1 
polymorphisms influence cyclosporin intracellular concentra-
tion; individuals homozygous for wild-type alleles presented 
a 1.8-fold decreased cyclosporin intracellular concentration 
(P = 0.04), compared to those with the mutant genotype.73 
Similar observations have been published for tacrolimus.74
Conclusion
Heterogeneity in the pharmacokinetics and pharmacodynam-
ics of immunosuppressive agents combined with their nar-
row therapeutic index renders them a difficult class of drug 
to prescribe. Selection of appropriate immunosuppressive 
regimens based on predicted risk of rejection and toxicity is 
only possible on a relatively crude basis at present but there 
is potential for refinement based on immunological and 
pharmacodynamic assays. We await the qualification of these 
potential biomarkers in clinical studies. In the meantime we 
are left with optimizing immunosuppressive drug prescribing 
based on pharmacokinetic measurements. Pharmacogenetic 
testing has potential as an adjunct to TDM in optimizing drug 
exposure. The only candidate pharmacogenetic strategy that 
has been tested in a clinical trial is CYP3A5 and tacrolimus 
but this strategy has not yet demonstrated definite clinical 
benefit. Refinement of dosing algorithms for tacrolimus based 
on all of the genes known to be involved in pharmacokinetics 
and demographic factors, followed by testing in a clinical trial 
with sufficient statistical power to demonstrate reduction in 
the incidence of rejection or toxicity, would be a logical next 
step. Further testing of pharmacogenetic strategies based on 
the CYP3A5 genotype is warranted for sirolimus. Clinical 
trials of other pharmacogenetic candidates would be prema-
ture at present. Genome wide association studies currently 
underway may identify further candidate genes.
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